Abstract
Background: Allergic rhinitis, one of the most common atopic diseases, is known to be elicited by Th2 cytokine-mediated inflammatory response. We have shown earlier that a polyol pathway enzyme aldose reductase (AR) regulates airway inflammation; however its role in allergic rhinitis is not known. We have investigated the role of AR in mediating pathological symptoms associated with allergic rhinitis in mice.
Methods: The wild-type (WT) mice treated without or with AR inhibitor and AR knock out (AR-/-) mice were sensitized by two intraperitoneal injections of ragweed pollen extract (RWE) with adjuvant alum on days 0 and 4 followed by challenge on day 11 and/or 18 and 25. The allergic rhinitis symptoms were assessed by monitoring the nasal scratch, mast cell degranulation and release of tryptase in nasal lavage, infiltration of inflammatory cells, production of inflammatory cytokines and nasal epithelium remodeling.
Results: Sensitization and challenge of mice with RWE produced robust and reproducible pathological symptoms of allergic rhinitis as compared to control mice. AR inhibitor, fidarestat administered mice showed markedly reduced early phase response to allergen exposure such as nasal scratches, mast cells degranulation and release of tryptase in the nasal passage as well as late phase response such as inflammatory cell infiltration and release of Th2 type cytokines and nasal epithelial remodeling. Further, prevention of these events in AR-/- mice suggests the role of AR in the mediation of allergic rhinitis.
Conclusion: These results indicate an important role of AR in the mediation of RWE-induced allergic rhinitis in mice and prevention by AR inhibitor, fidarestat offers a novel therapeutic approach to ameliorate allergic rhinitis.
Keywords: Aldose reductase, allergic rhinitis, fidarestat, ragweed pollen, Th2 cytokines.
Inflammation & Allergy - Drug Targets (Discontinued)
Title:Prevention of Allergic Rhinitis by Aldose Reductase Inhibition in a Murine Model
Volume: 12 Issue: 3
Author(s): Umesh C.S. Yadav, Rakesh Mishra, Leopoldo Aguilera-Aguirre, Sanjiv Sur, Istvan Bolodgh, Kota V. Ramana and Satish K. Srivatsava
Affiliation:
Keywords: Aldose reductase, allergic rhinitis, fidarestat, ragweed pollen, Th2 cytokines.
Abstract: Background: Allergic rhinitis, one of the most common atopic diseases, is known to be elicited by Th2 cytokine-mediated inflammatory response. We have shown earlier that a polyol pathway enzyme aldose reductase (AR) regulates airway inflammation; however its role in allergic rhinitis is not known. We have investigated the role of AR in mediating pathological symptoms associated with allergic rhinitis in mice.
Methods: The wild-type (WT) mice treated without or with AR inhibitor and AR knock out (AR-/-) mice were sensitized by two intraperitoneal injections of ragweed pollen extract (RWE) with adjuvant alum on days 0 and 4 followed by challenge on day 11 and/or 18 and 25. The allergic rhinitis symptoms were assessed by monitoring the nasal scratch, mast cell degranulation and release of tryptase in nasal lavage, infiltration of inflammatory cells, production of inflammatory cytokines and nasal epithelium remodeling.
Results: Sensitization and challenge of mice with RWE produced robust and reproducible pathological symptoms of allergic rhinitis as compared to control mice. AR inhibitor, fidarestat administered mice showed markedly reduced early phase response to allergen exposure such as nasal scratches, mast cells degranulation and release of tryptase in the nasal passage as well as late phase response such as inflammatory cell infiltration and release of Th2 type cytokines and nasal epithelial remodeling. Further, prevention of these events in AR-/- mice suggests the role of AR in the mediation of allergic rhinitis.
Conclusion: These results indicate an important role of AR in the mediation of RWE-induced allergic rhinitis in mice and prevention by AR inhibitor, fidarestat offers a novel therapeutic approach to ameliorate allergic rhinitis.
Export Options
About this article
Cite this article as:
Yadav C.S. Umesh, Mishra Rakesh, Aguilera-Aguirre Leopoldo, Sur Sanjiv, Bolodgh Istvan, Ramana V. Kota and Srivatsava K. Satish, Prevention of Allergic Rhinitis by Aldose Reductase Inhibition in a Murine Model, Inflammation & Allergy - Drug Targets (Discontinued) 2013; 12 (3) . https://dx.doi.org/10.2174/1871528111312030004
DOI https://dx.doi.org/10.2174/1871528111312030004 |
Print ISSN 1871-5281 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4055 |
Related Articles
-
Acetaminophen Oxidation and Inflammatory Markers – A Review of Hepatic Molecular Mechanisms and Preclinical Studies
Current Drug Targets Preventative and Therapeutic Potential of Lipopolysaccharide Derived from Edible Gram-Negative Bacteria to Various Diseases
Current Drug Therapy Pathogenesis of Acute Kidney Injury During Sepsis
Current Drug Targets Neuroimaging of Gut Nutrient Perception
Current Pharmaceutical Design CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Meet Our Editorial Board Member
Current Medicinal Chemistry Fighting with the Enemys Weapons? The Role of Costimulatory Molecules in HIV
Current Molecular Medicine Metabolic Therapy: Lessons from Liver Diseases
Current Pharmaceutical Design Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
Current Pharmaceutical Design Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Current Pharmaceutical Design Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets Effect of TRAF1 on Phenotypic Changes Of Kupffer Cells In Liver Transplantation Ischemic-Reperfusion
Current Pharmaceutical Biotechnology The Hunt for New Tuberculosis Vaccines: Anti-TB Immunity and Rational Design of Vaccines
Current Pharmaceutical Design Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry HIV-Induced Abnormalities in Myelopoiesis and their Recovery Following Antiretroviral Therapy
Current HIV Research Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Anti-metastatic and Anti-angiogenic Properties of Potential New Anti-cancer Drugs Based on Metal Complexes of Selenosemicarbazones
Anti-Cancer Agents in Medicinal Chemistry